Vetere, G., Sun, R., Morris, V. K., Dasari, A., Kee, B. K., Shen, J. P. Y., Willis, J., Morelli, M. P., Sorokin, A., Marie, P. K., Wolff, R. A., Overman, M. J., Raghav, K. P. S., Sanchez, E. V., Huey, R. W., Higbie, V., Le, P., Baig, Y., Kopetz, S., Parseghian, C. (2025). Open-label phase Ib/II study of cetuximab (CET) plus LY3214996 with or without abemaciclib in patients (pts) with anti-EGFR-refractory metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.3534